1. Lang R, Gundlach AL, Holmes FE.;et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev. 2015; 67(1): 118-75. http://dx.doi.org/10.1124/pr.112.006536 PMID: 25428932
2. Administration,of,antibodies,that,immune-specifically,bind,to,human,galanin,for,the,treatment,of,various,types,of,cancer.; with,the,genes,encoding,galanin,and,its,receptors,amplified,and/or,overexpressed. . .
3. The,use,of,galanin,antagonists.; as,an,antagonist,of,T-cells.; in,combination,with,antagonists,of,cytokine,CXCL10 for,the,treatme,nt,of,auto-immune,diseases.; such,as,diabetes,type,1. . .
4. Administration of agonists of GALR1 for the treatment of chronic or neuropathic pain. [63,73] The present invention relates to the modulation of galanin-like receptor interactions with PDZ (postsynaptic density protein of 95 kilodal-tons, disc large, zone occludens-1) domain-containing proteins for the treatment of neurological diseases, immune response dise ases, muscu-lar diseases, and cancer
5. Administration,of,the,galanin-peptide-binding,domain,to,decrease,leptin,(the,level.; expression.; or,activity) for,the,treatment,of,immune-related,disorders,such,as,intestinal,inflammatory,disease.; autoimmune,diseases,(for,example.; arthritis.; diabetes.; or,immune-rel,ated,infertility,disorders).;and,cancer. . .